A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Oct 2019
Price : $35 *
At a glance
- Drugs Daratumumab/hyaluronidase (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms AQUILA
- Sponsors Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag
- 25 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 09 Jan 2019 Planned End Date changed from 31 Dec 2025 to 22 Dec 2025.
- 15 Jun 2018 Planned End Date changed from 22 Dec 2025 to 31 Dec 2025.